WORCESTER, Mass.--(BUSINESS WIRE)--RXi Pharmaceuticals Corporation (Nasdaq:RXII), a biopharmaceutical company pursuing the development and commercialization of proprietary therapeutics based on RNA interference (RNAi), today announced that the Company’s President and Chief Executive Officer, Noah D. Beerman, will present a corporate overview at the 2010 BIO CEO & Investor Conference on Monday, February 8, 2010 at 11:30 a.m. ET.
